AR054254A1 - Terapia adyuvante con trastuzumab (herceptin registrado) - Google Patents
Terapia adyuvante con trastuzumab (herceptin registrado)Info
- Publication number
- AR054254A1 AR054254A1 AR20060101586A ARP060101586A AR054254A1 AR 054254 A1 AR054254 A1 AR 054254A1 AR 20060101586 A AR20060101586 A AR 20060101586A AR P060101586 A ARP060101586 A AR P060101586A AR 054254 A1 AR054254 A1 AR 054254A1
- Authority
- AR
- Argentina
- Prior art keywords
- herceptin
- trastuzumab
- therapy
- adjutive
- registered
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Primary Health Care (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Medical Informatics (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Business, Economics & Management (AREA)
- Tourism & Hospitality (AREA)
- Strategic Management (AREA)
Abstract
La presente solicitud describe la terapia adyuvante del cáncer de mama no metastásico que emplea trastuzumab (HERCEPTIN«) Reivindicacion 1: Uso de una cantidad efectiva de un anticuerpo que se une al Dominio IV de HER2 unido por trastuzumab (HERCEPTIN«) y al menos un agente quimioterapéutico en terapia adyuvante de un sujeto humano con cáncer de mama no metastásico HER2 positivo, después de cirugía definitiva, para prolongar la supervivencia libre de enfermedad (DFS) o supervivencia global (OS) en el sujeto, donde la DFS o la OS se evalua aproximadamente 2 a 5 anos después de la iniciacion del tratamiento.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68112505P | 2005-05-13 | 2005-05-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR054254A1 true AR054254A1 (es) | 2007-06-13 |
Family
ID=37450489
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AR20060101586A AR054254A1 (es) | 2005-05-13 | 2006-04-21 | Terapia adyuvante con trastuzumab (herceptin registrado) |
ARP120103682A AR088110A2 (es) | 2005-05-13 | 2012-10-03 | Uso de un inmunoconjugado que comprende un anticuerpo anti-erbb2 para la manufactura de un medicamento |
ARP170101287A AR109246A2 (es) | 2005-05-13 | 2017-05-15 | USO DE UN INMUNOCONJUGADO QUE COMPRENDE UN ANTICUERPO ANTI-ErbB2 PARA LA MANUFACTURA DE UN MEDICAMENTO |
ARP170101322A AR108615A2 (es) | 2005-05-13 | 2017-05-17 | Terapia adyuvante con herceptin® |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120103682A AR088110A2 (es) | 2005-05-13 | 2012-10-03 | Uso de un inmunoconjugado que comprende un anticuerpo anti-erbb2 para la manufactura de un medicamento |
ARP170101287A AR109246A2 (es) | 2005-05-13 | 2017-05-15 | USO DE UN INMUNOCONJUGADO QUE COMPRENDE UN ANTICUERPO ANTI-ErbB2 PARA LA MANUFACTURA DE UN MEDICAMENTO |
ARP170101322A AR108615A2 (es) | 2005-05-13 | 2017-05-17 | Terapia adyuvante con herceptin® |
Country Status (6)
Country | Link |
---|---|
US (5) | US8591897B2 (es) |
JP (9) | JP2006316040A (es) |
AR (4) | AR054254A1 (es) |
BR (1) | BRPI0601736A (es) |
CA (2) | CA2540547C (es) |
MX (1) | MX344809B (es) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
CN102698265A (zh) | 2000-05-19 | 2012-10-03 | 杰南技术公司 | 用于提高对ErbB 拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
GT200500155A (es) * | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
KR20180091967A (ko) | 2004-07-22 | 2018-08-16 | 제넨테크, 인크. | Her2 항체 조성물 |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
WO2006063042A2 (en) * | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
KR20170134771A (ko) | 2005-01-21 | 2017-12-06 | 제넨테크, 인크. | Her 항체의 고정 용량 투여법 |
KR101253576B1 (ko) | 2005-02-23 | 2013-04-11 | 제넨테크, 인크. | Her 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장 |
PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
TWI557138B (zh) | 2006-01-20 | 2016-11-11 | 建南德克公司 | 抗-ephrinb2抗體及使用該抗體的方法 |
EP1913958B1 (en) * | 2006-08-03 | 2009-12-23 | Sanofi-Aventis | Antitumor compositions containing acetylcyclopropyl docetaxel and trastuzumab |
JP2010516741A (ja) * | 2007-01-29 | 2010-05-20 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | モルホリニルアントラサイクリンおよび抗体を含む抗腫瘍の組み合わせ |
EP2899541A1 (en) | 2007-03-02 | 2015-07-29 | Genentech, Inc. | Predicting response to a HER dimerisation inhbitor based on low HER3 expression |
KR100972618B1 (ko) | 2007-10-19 | 2010-07-27 | 국립암센터 | 허셉틴을 이용한 유방암 진단 키트, 조성물 및 이들을이용하여 허셉틴 민감성 her2 과발현 세포를 검출하는방법 |
EP2235536A4 (en) * | 2007-12-20 | 2011-05-04 | Lab Corp America Holdings | HER-2 DIAGNOSTIC METHODS |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
BRPI0906049A8 (pt) | 2008-03-14 | 2018-06-26 | Genentech Inc | método para determinar se um câncer em um paciente é resistente ao tratamento com um agente antimitótico, método para tratar um paciente com câncer que é resistente ao agente antimitótico e método de tratamento |
HUE025507T2 (en) * | 2008-03-18 | 2016-02-29 | Genentech Inc | Combinations of anti-HER2 antibody-drug conjugate and chemotherapeutic agents and methods for their use |
WO2009131673A1 (en) * | 2008-04-25 | 2009-10-29 | Ludwig Institute For Cancer Research Ltd. | Targeted treatment for subjects with estrogen receptor negative and progesterone receptor negative breast cancers |
ES2342646B1 (es) * | 2008-06-02 | 2011-04-26 | Institut De Recerca Hospital Universitari Vall Hebron | Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas. |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
JP5644110B2 (ja) | 2008-08-05 | 2014-12-24 | 東レ株式会社 | 癌の検出方法 |
KR101667319B1 (ko) | 2008-08-05 | 2016-10-18 | 도레이 카부시키가이샤 | 암의 치료 및 예방용 의약 조성물 |
EP2362783A2 (en) | 2008-10-31 | 2011-09-07 | Biogen Idec MA Inc. | Light targeting molecules and uses thereof |
CA2764386C (en) | 2008-12-01 | 2018-05-01 | Laboratory Corporation Of America Holdings | P95-her2 antibodies and uses thereof |
MX2011006167A (es) * | 2008-12-11 | 2011-07-28 | Abraxis Bioscience Llc | Combinaciones y modos de administracion de agentes terapeuticos y terapia de combinacion. |
SG172983A1 (en) | 2009-01-15 | 2011-08-29 | Lab Corp America Holdings | Methods of determining patient response by measurement of her-3 |
CN102439452B (zh) * | 2009-01-15 | 2015-04-15 | 美国控股实验室公司 | 通过测量her-2表达确定患者应答的方法 |
KR20120050462A (ko) * | 2009-07-31 | 2012-05-18 | 엔도사이트, 인코포레이티드 | 엽산-표적화된 진단법 및 처치법 |
WO2011096519A1 (ja) | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
PL2532367T3 (pl) | 2010-02-04 | 2019-02-28 | Toray Industries, Inc. | Środek farmaceutyczny do leczenia i/lub zapobiegania nowotworu |
JP5742714B2 (ja) | 2010-02-04 | 2015-07-01 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
EP2532743B1 (en) | 2010-02-04 | 2015-04-15 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
DK2532364T3 (en) | 2010-02-04 | 2016-08-15 | Toray Industries | PHARMACEUTICAL COMPOSITION CONTAINING ANTI CAPRIN-1 ANTIBODIES FOR TREATMENT AND / OR PREVENTION OF CANCER |
RU2597971C2 (ru) | 2010-02-04 | 2016-09-20 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
RU2013131232A (ru) * | 2010-12-09 | 2015-01-20 | Дженентек, Инк. | Лечение her2-позитивного рака при помощи паклитаксела и трастузумаба-mсc-dm1 |
CN103764825B (zh) | 2011-08-04 | 2015-09-02 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
WO2013018894A1 (ja) | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
JP6015448B2 (ja) | 2011-08-04 | 2016-10-26 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
BR112014002619A2 (pt) | 2011-08-04 | 2018-10-09 | Toray Industries, Inc | composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica |
KR101968499B1 (ko) | 2011-08-04 | 2019-04-12 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
JP6065590B2 (ja) | 2011-08-04 | 2017-01-25 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
BR112014002616B1 (pt) | 2011-08-04 | 2022-01-18 | Toray Industries, Inc | Método para detectar câncer pancreático |
US20130095172A1 (en) | 2011-10-14 | 2013-04-18 | Genentech, Inc. | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
IN2014KN01716A (es) | 2012-02-21 | 2015-10-23 | Toray Industries | |
PL2818483T3 (pl) | 2012-02-21 | 2018-01-31 | Toray Industries | Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi |
CA2864999C (en) | 2012-02-21 | 2020-06-30 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
PL2818482T3 (pl) | 2012-02-21 | 2019-11-29 | Toray Industries | Kompozycja farmaceutyczna do leczenia nowotworu |
CN104203281B (zh) | 2012-03-30 | 2019-07-26 | 东丽株式会社 | 胆囊癌的治疗和/或预防用药物组合物 |
EP2832365B1 (en) | 2012-03-30 | 2017-11-01 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
KR102056654B1 (ko) | 2012-07-19 | 2019-12-17 | 도레이 카부시키가이샤 | 암의 검출 방법 |
CN104471404B (zh) | 2012-07-19 | 2017-03-01 | 东丽株式会社 | 癌的检测方法 |
WO2014169067A1 (en) * | 2013-04-09 | 2014-10-16 | Merrimack Pharmaceuticals, Inc. | Compositions for improving outcomes of liposomal chemotherapy |
CA3071678A1 (en) | 2013-04-16 | 2014-10-23 | Genentech,Inc. | Pertuzumab variants and evaluation thereof |
TR201819812T4 (tr) | 2013-08-09 | 2019-01-21 | Toray Industries | Kanserin Tedavisi Ve/Veya Önlenmesi Amacına Yönelik Farmasötik Bileşim |
SG10201809411PA (en) | 2014-04-25 | 2018-11-29 | Genentech Inc | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
TWI695011B (zh) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗her2表位之單株抗體及其使用之方法 |
WO2015195925A1 (en) | 2014-06-18 | 2015-12-23 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates and methods of using same |
CN107614015A (zh) | 2015-05-30 | 2018-01-19 | 豪夫迈·罗氏有限公司 | 治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法 |
SI3319995T1 (sl) * | 2015-07-07 | 2019-07-31 | F. Hoffmann-La Roche Ag | Kombinirana terapija s konjugatom protitelo anti-HER-2 in zdravilo ter zaviralcem bcl-2 |
US11554138B2 (en) | 2015-07-16 | 2023-01-17 | The University Of Hong Kong | Bismuth(III) complexes as adjuvants in the treatment of cancer using platinum-based chemotherapy |
WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
EP3493790A4 (en) * | 2016-08-02 | 2020-03-25 | Curirx Inc. | LIPOSOME PREPARATION METHODS |
US11110108B2 (en) * | 2016-09-27 | 2021-09-07 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
CN110099926A (zh) | 2016-12-28 | 2019-08-06 | 豪夫迈·罗氏有限公司 | 晚期her2表达性癌症的治疗 |
CR20190376A (es) | 2017-01-17 | 2019-11-20 | Genentech Inc | Formulaciones de anticuerpos de her2 subcutáneas |
ES2955074T3 (es) | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteínas que se unen a HER2, NKG2D Y CD16 |
EP3589661B1 (en) | 2017-03-02 | 2023-11-01 | Genentech, Inc. | Adjuvant treatment of her2-positive breast cancer |
TW201902509A (zh) | 2017-04-24 | 2019-01-16 | 美商建南德克公司 | Erbb2/her2突變 |
CN111278894A (zh) | 2017-07-06 | 2020-06-12 | 学校法人京都药科大学 | 肾脏靶向药物递送载体 |
BR112020016190A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Domínios variáveis de anticorpos direcionando o receptor nkg2d |
CN109739435B (zh) * | 2018-12-03 | 2023-10-13 | 中科恒运股份有限公司 | 文件存储和更新方法及装置 |
IL303350A (en) | 2020-12-04 | 2023-08-01 | Macrogenics Inc | Preparations containing an antibody against HER2/NEU and their use |
IL308025A (en) | 2021-04-29 | 2023-12-01 | Hyslink Therapeutics | Method of preparation and application of drug-antibody conjugate |
CA3223304A1 (en) | 2021-06-17 | 2022-12-22 | Minghui Pharmaceutical (Hangzhou) Limited | Antitumor compound and its application |
US20230295348A1 (en) | 2022-01-24 | 2023-09-21 | Novimmune Sa | Composition and methods for the selective activation of cytokine signaling pathways |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4935341A (en) | 1986-06-04 | 1990-06-19 | Whitehead Institute For Biomedical Research | Detection of point mutations in neu genes |
US7838216B1 (en) | 1986-03-05 | 2010-11-23 | The United States Of America, As Represented By The Department Of Health And Human Services | Human gene related to but distinct from EGF receptor gene |
US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
DE69031120T2 (de) | 1989-05-19 | 1998-01-15 | Genentech Inc | Her2 extrazellulare domäne |
US5705157A (en) | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
US6884418B1 (en) | 1989-08-04 | 2005-04-26 | Berlex Laboratories, Inc. | Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy |
WO1991002062A2 (en) | 1989-08-04 | 1991-02-21 | Triton Biosciences, Inc. | C-erbb-2 external domain: gp75 |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
US5939531A (en) | 1991-07-15 | 1999-08-17 | Novartis Corp. | Recombinant antibodies specific for a growth factor receptor |
ATE176328T1 (de) | 1991-08-22 | 1999-02-15 | Becton Dickinson Co | Methoden und zusammensetzungen zur krebstherapie und zur vorhersagbarkeit der reaktionen auf diese behandlung |
WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
US5288477A (en) | 1991-09-27 | 1994-02-22 | Becton, Dickinson And Company | Method for prognosticating response to cancer therapy |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
AU5355594A (en) | 1992-10-09 | 1994-05-09 | Oncor, Inc. | Methods for the detection of chromosome structural abnormalities by (in situ) hybridization to fixed tissue |
US6733752B1 (en) | 1994-03-30 | 2004-05-11 | The Trustees Of The University Of Pennsylvania | Prevention of tumors with monoclonal antibodies against neu |
US20030108545A1 (en) | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
US5846749A (en) | 1994-10-12 | 1998-12-08 | The Regents Of The University Of California | Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination |
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US5783404A (en) | 1995-04-13 | 1998-07-21 | Amgen Inc. | Methods and compositions for determining HER-2/neu expression using monoclonal antibodies |
US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
WO1997000271A1 (en) | 1995-06-14 | 1997-01-03 | The Regents Of The University Of California | Novel high affinity human antibodies to tumor antigens |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US5925519A (en) | 1996-06-03 | 1999-07-20 | The Regents Of The University Of California | Genetic alterations associated with prostate cancer |
US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
PT950067E (pt) | 1996-11-27 | 2007-12-06 | Genentech Inc | Purificação por afinidade de um polipéptido numa matriz de proteína a. |
US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
US20020076695A1 (en) | 1997-04-04 | 2002-06-20 | Jeffrey S. Ross | Methods for treating prostate cancer |
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
US6358682B1 (en) | 1998-01-26 | 2002-03-19 | Ventana Medical Systems, Inc. | Method and kit for the prognostication of breast cancer |
US20020192211A1 (en) | 1998-03-17 | 2002-12-19 | Hudziak Robert M. | Method of treating tumor cells by inhibiting growth factor receptor function |
AU765003B2 (en) | 1998-03-27 | 2003-09-04 | Genentech Inc. | Apo-2 ligand-anti-her-2 antibody synergism |
AU760048B2 (en) | 1998-05-06 | 2003-05-08 | Genentech Inc. | Protein purification by ion exchange chromatography |
SE512710C2 (sv) | 1998-07-08 | 2000-05-02 | Ericsson Telefon Ab L M | Kapsel för högeffekttransistorchip för höga frekvenser innefattande en elektriskt och termiskt ledande fläns |
US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
CA2357525A1 (en) | 1999-01-27 | 2000-08-03 | Cornell Research Foundation, Inc. | Treating cancers associated with overexpression of her-2/neu |
US6333348B1 (en) | 1999-04-09 | 2001-12-25 | Aventis Pharma S.A. | Use of docetaxel for treating cancers |
EP1187632B1 (en) * | 1999-05-14 | 2008-12-03 | Genentech, Inc. | TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
JP3485252B2 (ja) | 1999-06-16 | 2004-01-13 | インターナショナル・ビジネス・マシーンズ・コーポレーション | 情報処理方法、情報端末支援サーバ、コラボレーション・システム、情報処理プログラムを格納する記憶媒体 |
US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
EP2283867B1 (en) * | 1999-06-25 | 2014-05-21 | ImmunoGen, Inc. | Methods of treatment using anti-ERBB antibody-maytansinoid conjugates |
US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
TR200200472T2 (tr) * | 1999-08-27 | 2002-06-21 | Genentech, Inc. | Anti-Erb B2 antikorları ile tedavi için dozajlar |
US7303749B1 (en) | 1999-10-01 | 2007-12-04 | Immunogen Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
CA2385528C (en) | 1999-10-01 | 2013-12-10 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
CA2397349A1 (en) | 2000-02-29 | 2001-09-07 | Ivan David Horak | Farnesyl protein transferase inhibitor combinations with an her2 antibody |
US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
US6767541B2 (en) | 2000-03-20 | 2004-07-27 | The Regents Of The University Of California | HER-2/neu overexpression abrogates growth inhibitory pathways |
US20030152572A1 (en) | 2000-04-06 | 2003-08-14 | Yoshimi Homma | Diagnostic and therapeutic agents for rheumatoid arthritis |
GB0008368D0 (en) | 2000-04-06 | 2000-05-24 | Astrazeneca Ab | Combination product |
US7306801B2 (en) | 2000-05-15 | 2007-12-11 | Health Research, Inc. | Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein |
CN102698265A (zh) | 2000-05-19 | 2012-10-03 | 杰南技术公司 | 用于提高对ErbB 拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
TWI317285B (en) | 2000-07-28 | 2009-11-21 | Dainippon Sumitomo Pharma Co | New use and kit for remedies for cancer |
US6984494B2 (en) | 2000-08-15 | 2006-01-10 | Genentech, Inc. | Analytical method |
US6582919B2 (en) | 2001-06-11 | 2003-06-24 | Response Genetics, Inc. | Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates |
US20020142328A1 (en) | 2000-12-01 | 2002-10-03 | Danenberg Kathleen D. | Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors |
JP2004536561A (ja) | 2000-12-01 | 2004-12-09 | レスポンス ジェネティクス,インコーポレイティド | 上皮増殖因子受容体及びHER2−neu遺伝子発現並びにそれらのレベルと生存との相関関係を決定する方法 |
US7005278B2 (en) | 2001-03-02 | 2006-02-28 | Danenberg Kathleen D | Method of determining dihydropyrimidine dehydrogenase gene expression |
US6602670B2 (en) | 2000-12-01 | 2003-08-05 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 expression |
AU2002239486A1 (en) | 2000-12-08 | 2002-06-18 | Uab Research Foundation | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody |
WO2002087619A1 (fr) | 2001-04-27 | 2002-11-07 | Takeda Chemical Industries, Ltd. | Methode de prevention et de traitement du cancer |
US20030068318A1 (en) | 2001-09-28 | 2003-04-10 | O'brien Timothy | Treatment of uterine serous papillary cancer |
US20030175845A1 (en) | 2002-03-13 | 2003-09-18 | Kalbag Suresh M. | Use of sulfitolysis in high performance peptide mapping |
US20030190689A1 (en) | 2002-04-05 | 2003-10-09 | Cell Signaling Technology,Inc. | Molecular profiling of disease and therapeutic response using phospho-specific antibodies |
SI1501856T1 (sl) | 2002-04-10 | 2013-04-30 | Genentech, Inc. | Variante protitelesa proti HER2 |
ITTO20020340A1 (it) | 2002-04-19 | 2003-10-20 | Biother Di Contardi Gabriella | Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato. |
US20030202973A1 (en) | 2002-04-29 | 2003-10-30 | Dr. George Pieczenik | Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists |
US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
KR20050000544A (ko) | 2002-05-17 | 2005-01-05 | 아방티 파르마 소시에테 아노님 | 유방암 및 난소암의 보조 요법에서도세탁셀/독소루비신/사이클로포스파미드의 용도 |
PT2263691E (pt) | 2002-07-15 | 2012-11-12 | Hoffmann La Roche | Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4) |
US20040013297A1 (en) | 2002-07-18 | 2004-01-22 | Roger Lo | Method for performing color gamut compression |
EP3388452A3 (en) | 2002-09-11 | 2019-02-20 | Genentech, Inc. | Protein purification |
AU2003295798B2 (en) | 2002-11-21 | 2009-09-10 | Genentech, Inc. | Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies |
US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
CA2737127C (en) * | 2003-05-14 | 2016-07-26 | Immunogen, Inc. | Maytansinoid-antibody conjugate compositions |
-
2005
- 2005-10-25 JP JP2005310518A patent/JP2006316040A/ja active Pending
-
2006
- 2006-03-21 CA CA2540547A patent/CA2540547C/en active Active
- 2006-03-21 CA CA2790058A patent/CA2790058C/en active Active
- 2006-04-06 US US11/400,638 patent/US8591897B2/en active Active
- 2006-04-21 MX MX2013009514A patent/MX344809B/es unknown
- 2006-04-21 AR AR20060101586A patent/AR054254A1/es unknown
- 2006-04-25 BR BRPI0601736-3A patent/BRPI0601736A/pt not_active Application Discontinuation
-
2011
- 2011-08-08 US US13/205,523 patent/US8597654B2/en active Active
-
2012
- 2012-10-03 AR ARP120103682A patent/AR088110A2/es unknown
-
2013
- 2013-04-25 JP JP2013092728A patent/JP6133668B2/ja active Active
- 2013-05-24 JP JP2013109685A patent/JP2013163694A/ja active Pending
- 2013-10-25 US US14/063,885 patent/US20140086940A1/en not_active Abandoned
-
2015
- 2015-07-14 JP JP2015140158A patent/JP2015187168A/ja not_active Withdrawn
-
2017
- 2017-02-09 US US15/428,807 patent/US20180236093A1/en not_active Abandoned
- 2017-04-27 JP JP2017088351A patent/JP2017132805A/ja not_active Withdrawn
- 2017-04-27 JP JP2017088352A patent/JP2017132806A/ja active Pending
- 2017-05-15 AR ARP170101287A patent/AR109246A2/es unknown
- 2017-05-17 AR ARP170101322A patent/AR108615A2/es unknown
-
2018
- 2018-10-25 JP JP2018200936A patent/JP2019011374A/ja active Pending
-
2020
- 2020-01-30 US US16/777,345 patent/US20200155701A1/en not_active Abandoned
- 2020-03-11 JP JP2020041610A patent/JP2020094061A/ja not_active Withdrawn
-
2022
- 2022-05-02 JP JP2022075920A patent/JP2022093642A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2790058C (en) | 2019-01-15 |
JP2017132805A (ja) | 2017-08-03 |
JP2020094061A (ja) | 2020-06-18 |
JP2017132806A (ja) | 2017-08-03 |
CA2540547C (en) | 2016-08-16 |
AR109246A2 (es) | 2018-11-14 |
US8591897B2 (en) | 2013-11-26 |
JP6133668B2 (ja) | 2017-05-24 |
US20140086940A1 (en) | 2014-03-27 |
US20120003217A1 (en) | 2012-01-05 |
CA2540547A1 (en) | 2006-11-13 |
JP2006316040A (ja) | 2006-11-24 |
US20180236093A1 (en) | 2018-08-23 |
JP2013144718A (ja) | 2013-07-25 |
JP2019011374A (ja) | 2019-01-24 |
AR088110A2 (es) | 2014-05-07 |
JP2013163694A (ja) | 2013-08-22 |
JP2022093642A (ja) | 2022-06-23 |
US20060275305A1 (en) | 2006-12-07 |
US8597654B2 (en) | 2013-12-03 |
AR108615A2 (es) | 2018-09-12 |
MX344809B (es) | 2017-01-09 |
CA2790058A1 (en) | 2006-11-13 |
JP2015187168A (ja) | 2015-10-29 |
US20200155701A1 (en) | 2020-05-21 |
BRPI0601736A (pt) | 2007-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR054254A1 (es) | Terapia adyuvante con trastuzumab (herceptin registrado) | |
AR074360A1 (es) | Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
CL2017001580A1 (es) | Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped. | |
PE20080663A1 (es) | Terapia tumoral con una combinacion de anticuerpos anti-her2 | |
AR074203A1 (es) | Terapia anti-angiogenesis para el tratamiento del cancer de mama. kit. uso. | |
CO6150193A2 (es) | Terapia tumoral con anticuerpo anti-vegf | |
AR065589A1 (es) | Prediccion de respuesta a un inhibidor her | |
AR076344A1 (es) | Metodo de terapia complementaria contra el cancer | |
CL2007001624A1 (es) | Uso de un anticuerpo que se une a dll4 para el tratamiento de tumor, cancer o trastorno de proliferacion celular. | |
DOP2012000291A (es) | 4-yodo-3-nitrobenzamida en combinacion con agentes anti-tumorales para el uso en el tratamiento de cancer de mama | |
CO6140062A2 (es) | Anticuerpos anti-trop-2 humanizados y quiméricos que median citotoxicidad de celulas cancerosas | |
PE20170903A1 (es) | Conjugados de farmacos con anticuerpos anti-cdh6 | |
UA94899C2 (ru) | Фиксированное дозирование антител к her | |
PE20060461A1 (es) | Combinacion de un anticuerpo her2 y gemcitabina para el tratamiento de cancer resistente al platino | |
PA8635501A1 (es) | Uso de un anticuerpo para el tratamiento del lupus | |
JP2012046518A5 (es) | ||
ECSP088636A (es) | Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos, y métodos de uso en la terapia de cáncer | |
EA200970923A1 (ru) | АНТИ-EpСАМ АНТИТЕЛО И ЕГО ПРИМЕНЕНИЕ | |
PE20120902A1 (es) | Anticuerpos anti-egfl7 humanizados | |
BR0210550A (pt) | Método para realçar a eficácia de terapias contra o câncer | |
AR074778A1 (es) | Composicion farmaceutica, con anticuerpo monoclonal humano anti - igf-ir. | |
CL2021001260A1 (es) | Anticuerpos anti-sirpa humanizados | |
CR10996A (es) | Metodo de tratamiento del cancer mediante administracion de combinaciones de il-18 humana | |
PE20081553A1 (es) | Composicion farmaceutica que comprende un anticuerpo monoclonal anti cd6 utilizado en el diagnostico y tratamiento de la artritis reumatoide | |
BR112015027474A8 (pt) | anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |